Search Results - autm26c1

7 Results

Sort By:

Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders

NU 2025-113 (NU 2018-176, NU 2024-250, NU 2025-038) INVENTORS Richard Silverman (Weinberg College of Arts and Sciences, Department of Chemistry) SHORT DESCRIPTION Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer)...

Published: 2/6/2026 | Inventor(s):

Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Immunotherapy, Melanoma, Small molecule, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Selective DOT1L Protein Degraders for Precision Cancer Therapy

NU 2022-081 INVENTORS Sarki Abdulkadir (PI)* Gary Schiltz (PI)* SHORT DESCRIPTION A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate cancer. BACKGROUND Current cancer treatments, especially for MLL-rearranged leukemia and prostate cancer, face challenges of off-target effects and...

Published: 2/6/2026 | Inventor(s):

Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics

SHORT DESCRIPTION Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy. INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* Jindan...

Published: 2/6/2026 | Inventor(s):

Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Targeted Therapy for Glioblastoma via Purine Metabolism Modulation

NU 2019-086 INVENTORS Atique Ahmed* Cheol Park Jack Shireman SHORT DESCRIPTION This technology introduces a targeted approach for glioblastoma treatment that modulates purine biosynthesis by targeting the ARL13B-IMPDH2 interaction using repurposed FDA-approved and internationally-used drugs. BACKGROUND Glioblastoma is an incurable, aggressive...

Published: 2/6/2026 | Inventor(s):

Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Repurposed Drugs, Therapeutics

Category(s): Life Sciences > Therapeutics

Compositions and Methods for the Treatment of Intestinal Inflammation

NU 2021-252 INVENTORS Matthew Bury Muthukumar Gunasekaran Sunjay Kaushal Arun Sharma* Tiffany Sharma BACKGROUND Crohn’s Disease (CD) is partly caused by a highly pro-inflammatory lesion microenvironment which subsequently causes numerous clinical complications. Northwestern University scientists have developed a method to control...

Published: 2/6/2026 | Inventor(s):

Keywords(s): AUTM26C1, BIAUTM1, Cell therapy, IBD - Inflammatory bowel disease, Immunotherapy, Infectious disease, Therapeutics

Category(s): Life Sciences > Therapeutics

Therapy for acute kidney injury

NU 2022-202 INVENTORS Pinelopi Kapitsinou* Ratnakar Tiwari SHORT DESCRIPTION Inhibition of MCT4 slows the progression of acute kidney inury to chronic kidney disease BACKGROUND Acute kidney inury (AKI) is a sudden onset of kidney dysfunction, often caused by factors such as ischemia, toxins, or infections, leading to impaired filtration and accumulation...

Published: 2/6/2026 | Inventor(s):

Keywords(s): AUTM26C1, BIAUTM1, Inflammation, Renal Disease, Therapeutics

Category(s): Life Sciences > Therapeutics

IDO-PROTACs for Improving the Anti-Cancer Immune Response

NU 2020-137 INVENTORS Derek Wainwright* Gary Schiltz SHORT DESCRIPTION IDO-PROTAC that target immunosuppressive IDO activity via degradation ABSTRACT The median survival of primary GBM patients following aggressive surgical intervention, radiotherapy,chemotherapy, and tumor treating fields (TTF) is only ~14-16 months. Indoleamine 2,3-dioxygenase...

Published: 2/6/2026 | Inventor(s):

Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Immunotherapy, Therapeutics

Category(s): Life Sciences > Therapeutics